Longitudinal study of circulating miR-122 in a rat model of non-alcoholic fatty liver disease

Clinica Chimica Acta

Volumn 446, Issue , 2015, Pages 267-271

  Yamada, Hiroya ^a   Ohashi, Koji ^b   Suzuki, Koji ^b   Munetsuna, Eiji ^a   Ando, Yoshitaka ^a   Yamazaki, Mirai ^b   Ishikawa, Hiroaki ^b   Ichino, Naohiro ^b   Teradaira, Ryouji ^b   Hashimoto, Shuji ^a  

^a FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b FUJITA HEALTH UNIVERSITY   (Japan)

Author keywords

Circulating miRNA; MiR 122; Non alcoholic fatty liver disease; Serum miRNA

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; CHOLESTEROL; FATTY ACID; MICRORNA 122; TRIACYLGLYCEROL; AZO COMPOUND; MICRORNA; MIRN122 MICRORNA, RAT; OIL RED O;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BIOACCUMULATION; BIOCHEMICAL ANALYSIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE COURSE; EARLY DIAGNOSIS; FATTY ACID BLOOD LEVEL; GENE FUNCTION; LIPID DIET; LIPID LIVER LEVEL; LIPID PEROXIDATION; LIPID STORAGE; LONGITUDINAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; RAT; REAL TIME POLYMERASE CHAIN REACTION; RNA ANALYSIS; TRIACYLGLYCEROL BLOOD LEVEL; UPREGULATION; WEIGHT GAIN; ANIMAL; BLOOD; CYTOCHEMISTRY; DISEASE MODEL; HUMAN; LIVER; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY; SPRAGUE DAWLEY RAT;

ANIMALIA; RATTUS;

ALANINE TRANSAMINASE; ANIMALS; ASPARTATE AMINOTRANSFERASES; AZO COMPOUNDS; BIOMARKERS; CHOLESTEROL; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; EARLY DIAGNOSIS; FATTY ACIDS, NONESTERIFIED; HISTOCYTOCHEMISTRY; HUMANS; LIVER; LONGITUDINAL STUDIES; MALE; MICRORNAS; NON-ALCOHOLIC FATTY LIVER DISEASE; RATS; RATS, SPRAGUE-DAWLEY; TRIGLYCERIDES;

EID: 84929311817     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2015.05.002     Document Type: Article

References (22)

1. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
2. Cortez M.A., Bueso-Ramos C., Ferdin J., Lopez-Berestein G., Sood A.K., Calin G.A. MicroRNAs in body fluids-the mix of hormones and biomarkers. Nat Rev Clin Oncol 2011, 8:467-477.
3. Gilad S., Meiri E., Yogev Y., et al. Serum microRNAs are promising novel biomarkers. PLoS One 2008, 3:e3148.
4. McDonald J.S., Milosevic D., Reddi H.V., Grebe S.K., Algeciras-Schimnich A. Analysis of circulating microRNA: preanalytical and analytical challenges. Clin Chem 2011, 57:833-840.
5. Mitchell P.S., Parkin R.K., Kroh E.M., et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:10513-10518.
6. Carissimi C., Fulci V., Macino G. MicroRNAs: novel regulators of immunity. Autoimmun Rev 2009, 8:520-524.
7. Kong Y.W., Ferland-McCollough D., Jackson T.J., Bushell M. MicroRNAs in cancer management. Lancet Oncol 2012, 13:e249-e258.
8. Tiniakos D.G., Vos M.B., Brunt E.M. Nonalcoholic fatty liver disease: pathology and pathogenesis. Annu Rev Pathol 2010, 5:145-171.
9. Matteoni C.A., Younossi Z.M., Gramlich T., Boparai N., Liu Y.C., McCullough A.J. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999, 116:1413-1419.
10. Moscatiello S., Di Luzio R., Sasdelli A.S., Marchesini G. Managing the combination of nonalcoholic fatty liver disease and metabolic syndrome. Expert Opin Pharmacother 2011, 12:2657-2672.
11. Pacifico L., Nobili V., Anania C., Verdecchia P., Chiesa C. Pediatric nonalcoholic fatty liver disease, metabolic syndrome and cardiovascular risk. World J Gastroenterol 2011, 17:3082-3091.
12. Yamada H., Suzuki K., Ichino N., et al. Associations between circulating microRNAs (miR-21, miR-34a, miR-122 and miR-451) and non-alcoholic fatty liver. Clin Chim Acta 2013, 424:99-103.
13. Cermelli S., Ruggieri A., Marrero J.A., Ioannou G.N., Beretta L. Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. PLoS One 2011, 6:e23937.
14. Miyaaki H., Ichikawa T., Kamo Y., et al. Significance of serum and hepatic microRNA-122 levels in patients with non-alcoholic fatty liver disease. Liver Int 2014, 34:e302-e307.
15. Li Y.Y. Genetic and epigenetic variants influencing the development of nonalcoholic fatty liver disease. World J Gastroenterol 2012, 18:6546-6551.
16. Wong C.A., Araneta M.R., Barrett-Connor E., Alcaraz J., Castaneda D., Macera C. Probable NAFLD, by ALT levels, and diabetes among Filipino-American women. Diabetes Res Clin Pract 2008, 79:133-140.
17. Ohkawa H., Ohishi N., Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979, 95:351-358.
18. Yamada H., Itoh M., Hiratsuka I., Hashimoto S. Circulating microRNAs in autoimmune thyroid diseases. Clin Endocrinol (Oxf) 2014, 81:276-281.
19. Chen X., Ba Y., Ma L., et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008, 18:997-1006.
20. Jopling C. Liver-specific microRNA-122: biogenesis and function. RNA Biol 2012, 9:137-142.
21. Alisi A., Da Sacco L., Bruscalupi G., et al. Mirnome analysis reveals novel molecular determinants in the pathogenesis of diet-induced nonalcoholic fatty liver disease. Lab Invest 2011, 91:283-293.
22. Rolo A.P., Teodoro J.S., Palmeira C.M. Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Free Radic Biol Med 2012, 52:59-69.